Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Thalassemia Market 2016 Overview, Trend and Analysis

Friday, November 18, 2016 3:32
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Thalassemia is a hereditary blood disorder in which a person’s body makes an abnormal form of hemoglobin, which is the protein molecule in red blood cells (RBCs), which carries oxygen. The disorder results in unwarranted damage of red blood cells, which leads to anemia. Anemia is a condition in which the body doesn’t have adequate amount of normal and healthy red blood cells. There are majorly two types of thalassemia based on these proteins known as the Alpha thalassemia and the Beta thalassemia. There is also a third type viz. Sickle beta thalassemia, which is like a combination of sickle cell disease and beta thalassemia. 

Even though it is a rare genetic disorder, the number of people affected by it has been growing with time. While those with thalassemia minor have hardly any threat to their life and only require occasional blood transfusion to sustain, thalassemia major patients need to go for periodic transfusions for a sustained life. In case of infants, thalassemia major often leads to still birth or cause death shortly after the baby’s birth. Presently the only cure for thalassemia is a bone marrow transplantation therapy, which is done mostly for severe cases of thalassemia.

.For more information about this report: http://www.reportsweb.com/global-thalassemia-market-report-2016-edition .

The key factors which are anticipated to drive this market include rising healthcare expenditure, rising spending on stem cell therapy research and development and rising population in the East-Asia and Pacific region of the world. Some of the noteworthy developments of this industry include the advances in the iron chelation therapy, development of gene therapy and fetal hemoglobin inducers as potential curatives for thalassemia. However, the growth of respective industry is challenged by the high cost of treatments, lack of alternative treatments and unmet market of the Asia-Pacific.

The report provides a comprehensive study of global thalassemia market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global thalassemia industry is highly competitive consisting of several companies including the Lonza group, Acceleron Pharma, BlueBird Bio and Sangamo Biosciences etc. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

 

Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001263420/sample .

 

 Company Profiles 

6.1 Lonza Group Ltd 

6.1.1 Business Overview 
6.1.2 Financial Overview 
6.1.3 Business Strategies 

6.2 Bluebird Bio 

6.2.1 Business Overview 
6.2.2 Financial Overview 
6.2.3 Business Strategies 

6.3 Acceleron Pharma, Inc 

6.3.1 Business Overview 
6.3.2 Financial Overview 
6.3.3 Business Strategies 

6.4 Sangamo Biosciences 

6.4.1 Business Overview 
6.4.2 Financial Overview 
6.4.3 Business Strategies 
 

Make an enquiry: http://www.reportsweb.com/inquiry& RW0001263420/buying .

Contact Us:

Call: +1-646-491-9876
Email: sales@reportsweb.com

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.